ArticleInternational ophthalmology2019
Ocular surface squamous neoplasia: analysis based on the 8th American Joint Committee on Cancer classification.
Article in International ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Review
- High-resolution optical coherence tomography for screening ocular surface tumors: Historical markers and future directions.World journal of clinical cases · 2025Article
- Update in the Diagnosis and Management of Ocular Surface Squamous Neoplasia (OSSN).Journal of clinical medicine · 2025Review
- Novel automated non-invasive detection of ocular surface squamous neoplasia using artificial intelligence.World journal of methodology · 2024Review
- Clinicopathological Correlates of Ocular Surface Squamous Neoplasia.Ocular oncology and pathology · 2024Article
- Ocular surface squamous neoplasia in India: a study of 438 patients.International ophthalmology · 2022Article
- Exploring the Risk Factors of Conjunctival Squamous Cell Carcinoma and Establishing a Prognostic Model: Retrospective Study.Disease markers · 2022Article
- Ocular surface squamous neoplasia at a tertiary eye facility, Southwestern Nigeria: a 10-year review.International ophthalmology · 2021Article
- Update on the Management of Ocular Surface Squamous Neoplasia.Current ophthalmology reports · 2021Article
- Single-Fraction Adjuvant Electronic Brachytherapy after Resection of Conjunctival Carcinoma.Cancers · 2021Article
- Squamous cell carcinoma of the lacrimal punctum: A rare presentation.Indian journal of ophthalmology · 2020Article
- Management Issues in Conjunctival Tumours: Ocular Surface Squamous Neoplasia.Ophthalmology and therapy · 2020Article
- Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence.Ophthalmology and therapy · 2018Review
- Determining tumor category of ocular surface squamous neoplasia: science or art?Annals of translational medicine · 2018Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate outcomes of ocular surface squamous neoplasia (OSSN) based on American Joint Committee on Cancer (AJCC), 8th edition classification.
methodsRetrospective, non-randomized interventional case series of 127 patients (136 eyes) with OSSN.
resultsOn the basis of the AJCC (eighth edition), OSSN was classified as per T category as Tis (n = 14, 10%), T1 (n = 0), T2 (n = 4, 3%), T3 (n = 113, 83%), and T4 (n = 5, 4%). The following parameters increased with increasing T category: mean age at presentation at 37 years for Tis, 43 years for T2, 46 years for T3, and 55 years for T4 (p = 0.04); mean tumor basal diameter of 4 mm for Tis, not applicable (na) for T1, 6 mm for T2, 7 mm for T3, 20 mm for T4 (p = 0.001); extent of clock hours of corneal involvement (0, na, 0, 4, 8; p = 0.02), and conjunctival involvement (1, na, 2, 3, 9; p = 0.0005); involvement of adjacent structures including fornix (0%, na, 0, 9, 80%; p < 0.001), and caruncle (0%, na, 0, 3, 60%; p < 0.001) for Tis, T1, T2, T3, and T4, respectively. Overall, of the 136 eyes, 19 (14%) had tumor recurrence, and all tumor recurrences were seen in T3. Regional lymph node metastasis was noted in 4 (3%) patients. No systemic metastasis or death occurred in any patient during the mean follow-up period of 15 months (median, 11 months; range 6-55 months).
conclusionIncreasing T category based on AJCC 8th edition classification is associated with increasing severity of disease, tumor recurrence rate, and the rate of regional lymph node metastasis.
Indexed as
Identifiers
29749567What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.